Bicyclic Picomolar OGA Inhibitors Enable Chemoproteomic Mapping of Its Endogenous Post-translational Modifications.
暂无分享,去创建一个
L. Foster | G. Davies | M. González-Cuesta | C. Ortiz Mellet | J. G. García Fernández | D. Vocadlo | Jason C. Rogalski | A. Males | Roger A Ashmus | Peter Sidhu | Cameron Proceviat | Zarina Madden | Jil A. Busmann | J. Rogalski
[1] Oriol Vinyals,et al. Highly accurate protein structure prediction with AlphaFold , 2021, Nature.
[2] Yi Liang,et al. O‐GlcNAcylation of TDP‐43 suppresses proteinopathies and promotes TDP‐43’s mRNA splicing activity , 2021, EMBO reports.
[3] Jeet K. Vora,et al. The human O-GlcNAcome database and meta-analysis , 2021, Scientific Data.
[4] Daniel J. Corey,et al. Chemical Synthesis and Biological Applications of O‐GlcNAcylated Peptides and Proteins , 2021, Chembiochem : a European journal of chemical biology.
[5] Dingguo Xu,et al. Mechanistic Insights into the Hydrolysis of O-GlcNAcylation Catalyzed by Human O-GlcNAcase. , 2020, The journal of physical chemistry. B.
[6] Lynn A. Hyde,et al. MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy , 2020, The Journal of Pharmacology and Experimental Therapeutics.
[7] Eun Ju Kim. O‐GlcNAc Transferase: Structural Characteristics, Catalytic Mechanism and Small‐Molecule Inhibitors , 2020, Chembiochem : a European journal of chemical biology.
[8] M. Lai,et al. O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease , 2020, NeuroMolecular Medicine.
[9] G. Davies,et al. Molecular mechanisms regulating O-linked N-acetylglucosamine (O-GlcNAc)-processing enzymes. , 2019, Current opinion in chemical biology.
[10] D. Klein,et al. Discovery of MK-8719, A Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. , 2019, Journal of medicinal chemistry.
[11] Dustin J Maly,et al. Chemoproteomic Method for Profiling Inhibitor-Bound Kinase Complexes. , 2019, Journal of the American Chemical Society.
[12] P. Cohen,et al. The E3 ligase HOIL-1 catalyses ester bond formation between ubiquitin and components of the Myddosome in mammalian cells , 2019, Proceedings of the National Academy of Sciences.
[13] K. Higaki,et al. Pharmacological Chaperones for the Treatment of α-Mannosidosis. , 2019, Journal of medicinal chemistry.
[14] H. Bøtker,et al. The Role of O-GlcNAcylation for Protection against Ischemia-Reperfusion Injury , 2019, International journal of molecular sciences.
[15] D. V. van Aalten,et al. O-GlcNAcase Fragment Discovery with Fluorescence Polarimetry. , 2018, ACS chemical biology.
[16] K. Higaki,et al. Probing the Inhibitor versus Chaperone Properties of sp2-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease , 2018, Molecules.
[17] Sujata Sharma,et al. Insights into activity and inhibition from the crystal structure of human O-GlcNAcase. , 2017, Nature chemical biology.
[18] Xiaoyong Yang,et al. Protein O-GlcNAcylation: emerging mechanisms and functions , 2017, Nature Reviews Molecular Cell Biology.
[19] G. Davies,et al. Structural and functional insight into human O-GlcNAcase , 2017, Nature chemical biology.
[20] Jiaoyang Jiang,et al. Structures of human O-GlcNAcase and its complexes reveal a new substrate recognition mode , 2017, Nature Structural &Molecular Biology.
[21] Yoshiyuki Suzuki,et al. pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases. , 2015, Angewandte Chemie.
[22] Edward L. Huttlin,et al. Quantitative Proteomic Atlas of Ubiquitination and Acetylation in the DNA Damage Response. , 2015, Molecular cell.
[23] C. Ortiz Mellet,et al. Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease , 2015, Scientific Reports.
[24] M. Bergeron-Brlek,et al. Direct synthesis of imino-C-nucleoside analogues and other biologically active iminosugars , 2015, Nature Communications.
[25] Carsten Hopf,et al. Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. , 2014, ACS chemical biology.
[26] Yoshiyuki Suzuki,et al. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants. , 2014, ACS chemical biology.
[27] Steven P Gygi,et al. Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.
[28] W. Herr,et al. HCF-1 Is Cleaved in the Active Site of O-GlcNAc Transferase , 2013, Science.
[29] J. Bacik,et al. The Development of Selective Inhibitors of NagZ: Increased Susceptibility of Gram-Negative Bacteria to β-Lactams , 2013, Chembiochem : a European journal of chemical biology.
[30] B. G. Davis,et al. Glycomimetic affinity-enrichment proteomics identifies partners for a clinically-utilized iminosugar. , 2013, Chemical science.
[31] Steven A Carr,et al. Integrated proteomic analysis of post-translational modifications by serial enrichment , 2013, Nature Methods.
[32] J. I. Izpisúa Belmonte,et al. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. , 2013, Human molecular genetics.
[33] S. Walker,et al. Structural snapshots of the reaction coordinate for O-GlcNAc transferase , 2012, Nature chemical biology.
[34] T. Butters,et al. Scalable syntheses of both enantiomers of DNJNAc and DGJNAc from glucuronolactone: the effect of N-alkylation on hexosaminidase inhibition. , 2012, Chemistry.
[35] Y. Sakakibara,et al. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis. , 2012, Chemical communications.
[36] S. Larson,et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.
[37] Edward L. Huttlin,et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. , 2011, Molecular cell.
[38] K. Read,et al. Cell-Penetrant, Nanomolar O-GlcNAcase Inhibitors Selective against Lysosomal Hexosaminidases , 2010, Chemistry & biology.
[39] G. Davies,et al. Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes , 2010, Chemistry & biology.
[40] G. Davies,et al. Visualizing the reaction coordinate of an O-GlcNAc hydrolase. , 2010, Journal of the American Chemical Society.
[41] B. Winblad,et al. Affinity pulldown of γ-secretase and associated proteins from human and rat brain , 2009, Journal of cellular and molecular medicine.
[42] G. Davies,et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. , 2008, Nature chemical biology.
[43] Matthias Mann,et al. Nε-Formylation of lysine is a widespread post-translational modification of nuclear proteins occurring at residues involved in regulation of chromatin function , 2007, Nucleic acids research.
[44] J. Turkenburg,et al. Structure and mechanism of a bacterial β-glucosaminidase having O-GlcNAcase activity , 2006, Nature Structural &Molecular Biology.
[45] D. Murphy. Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. , 2004, Analytical biochemistry.
[46] G. Hart,et al. Dynamic Glycosylation of Nuclear and Cytosolic Proteins , 1997, The Journal of Biological Chemistry.